The diagnostic and prognostic value of a line immunoblot assay in Taiwanese patients with systemic sclerosis

Tsai Hung Yen; Jun Peng Chen; Tsu Yi Hsieh; Wei Ting Hung; Kuo Lung Lai; Chia Wei Hsieh; Hsin Hua Chen; Wen Nan Huang; Yi Hsing Chen; Yi Ming Chen

doi:10.1016/j.cca.2023.117457

The diagnostic and prognostic value of a line immunoblot assay in Taiwanese patients with systemic sclerosis

Tsai Hung Yen, Jun Peng Chen, Tsu Yi Hsieh, Wei Ting Hung, Kuo Lung Lai, Chia Wei Hsieh, Hsin Hua Chen, Wen Nan Huang, Yi Hsing Chen, Yi Ming Chen^*

^*Corresponding author for this work

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background and aims: We aimed to evaluate the diagnostic performance and prognostic value of disease-specific antibodies and anti-Ro52 using a commercial line immunoblot assay (LIA) in Taiwanese patients with systemic sclerosis (SSc). Materials and methods: We retrospectively enrolled all individuals at the Taichung Veterans General Hospital. We evaluated the diagnostic performance of LIA, anti-nuclear antibody (ANA) by indirect immunofluorescence (IIF) and also the association between the autoantibodies and the clinical phenotype using multivariable logistic regression. Results: The LIA exhibited a sensitivity of 65.4% and a specificity of 65.4%, at the optimal cutoff values of 2 + signal intensity. By taking the result of ANA into consideration, the optimal cutoff point was redefined as 1+. We observed a higher risk of diffuse cutaneous SSc (dcSSc) in those with negative autoantibodies, positive anti-Scl-70, anti-RNA polymerase III, and anti-Ro-52. Interstitial lung disease (ILD) was associated with negative autoantibodies, as well as positive anti-Scl-70 and anti-Ro52. Anti-Ro52 positivity was also associated with pulmonary arterial hypertension (PAH) and gastrointestinal tract involvement. Conclusion: The presence of anti-Ro52 or the absence of SSc-specific autoantibodies may potentially indicate advanced diseases in patients with SSc. The incorporation of both IIF and LIA testing may improve the diagnostic specificity of SSc.

Original language	English
Article number	117457
Journal	Clinica Chimica Acta
Volume	547
DOIs	https://doi.org/10.1016/j.cca.2023.117457
State	Published - 1 Jul 2023

Keywords

Anti-Ro52
Autoantibody
Immunoblot
Interstitial lung disease
Pulmonary arterial hypertension
Systemic sclerosis

Access to Document

10.1016/j.cca.2023.117457

Cite this

@article{fc63a024690b4153a6f12170b21a9b3b,

title = "The diagnostic and prognostic value of a line immunoblot assay in Taiwanese patients with systemic sclerosis",

abstract = "Background and aims: We aimed to evaluate the diagnostic performance and prognostic value of disease-specific antibodies and anti-Ro52 using a commercial line immunoblot assay (LIA) in Taiwanese patients with systemic sclerosis (SSc). Materials and methods: We retrospectively enrolled all individuals at the Taichung Veterans General Hospital. We evaluated the diagnostic performance of LIA, anti-nuclear antibody (ANA) by indirect immunofluorescence (IIF) and also the association between the autoantibodies and the clinical phenotype using multivariable logistic regression. Results: The LIA exhibited a sensitivity of 65.4% and a specificity of 65.4%, at the optimal cutoff values of 2 + signal intensity. By taking the result of ANA into consideration, the optimal cutoff point was redefined as 1+. We observed a higher risk of diffuse cutaneous SSc (dcSSc) in those with negative autoantibodies, positive anti-Scl-70, anti-RNA polymerase III, and anti-Ro-52. Interstitial lung disease (ILD) was associated with negative autoantibodies, as well as positive anti-Scl-70 and anti-Ro52. Anti-Ro52 positivity was also associated with pulmonary arterial hypertension (PAH) and gastrointestinal tract involvement. Conclusion: The presence of anti-Ro52 or the absence of SSc-specific autoantibodies may potentially indicate advanced diseases in patients with SSc. The incorporation of both IIF and LIA testing may improve the diagnostic specificity of SSc.",

keywords = "Anti-Ro52, Autoantibody, Immunoblot, Interstitial lung disease, Pulmonary arterial hypertension, Systemic sclerosis",

author = "Yen, {Tsai Hung} and Chen, {Jun Peng} and Hsieh, {Tsu Yi} and Hung, {Wei Ting} and Lai, {Kuo Lung} and Hsieh, {Chia Wei} and Chen, {Hsin Hua} and Huang, {Wen Nan} and Chen, {Yi Hsing} and Chen, {Yi Ming}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier B.V.",

year = "2023",

month = jul,

day = "1",

doi = "10.1016/j.cca.2023.117457",

language = "English",

volume = "547",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

}

TY - JOUR

T1 - The diagnostic and prognostic value of a line immunoblot assay in Taiwanese patients with systemic sclerosis

AU - Yen, Tsai Hung

AU - Chen, Jun Peng

AU - Hsieh, Tsu Yi

AU - Hung, Wei Ting

AU - Lai, Kuo Lung

AU - Hsieh, Chia Wei

AU - Chen, Hsin Hua

AU - Huang, Wen Nan

AU - Chen, Yi Hsing

AU - Chen, Yi Ming

PY - 2023/7/1

Y1 - 2023/7/1

N2 - Background and aims: We aimed to evaluate the diagnostic performance and prognostic value of disease-specific antibodies and anti-Ro52 using a commercial line immunoblot assay (LIA) in Taiwanese patients with systemic sclerosis (SSc). Materials and methods: We retrospectively enrolled all individuals at the Taichung Veterans General Hospital. We evaluated the diagnostic performance of LIA, anti-nuclear antibody (ANA) by indirect immunofluorescence (IIF) and also the association between the autoantibodies and the clinical phenotype using multivariable logistic regression. Results: The LIA exhibited a sensitivity of 65.4% and a specificity of 65.4%, at the optimal cutoff values of 2 + signal intensity. By taking the result of ANA into consideration, the optimal cutoff point was redefined as 1+. We observed a higher risk of diffuse cutaneous SSc (dcSSc) in those with negative autoantibodies, positive anti-Scl-70, anti-RNA polymerase III, and anti-Ro-52. Interstitial lung disease (ILD) was associated with negative autoantibodies, as well as positive anti-Scl-70 and anti-Ro52. Anti-Ro52 positivity was also associated with pulmonary arterial hypertension (PAH) and gastrointestinal tract involvement. Conclusion: The presence of anti-Ro52 or the absence of SSc-specific autoantibodies may potentially indicate advanced diseases in patients with SSc. The incorporation of both IIF and LIA testing may improve the diagnostic specificity of SSc.

AB - Background and aims: We aimed to evaluate the diagnostic performance and prognostic value of disease-specific antibodies and anti-Ro52 using a commercial line immunoblot assay (LIA) in Taiwanese patients with systemic sclerosis (SSc). Materials and methods: We retrospectively enrolled all individuals at the Taichung Veterans General Hospital. We evaluated the diagnostic performance of LIA, anti-nuclear antibody (ANA) by indirect immunofluorescence (IIF) and also the association between the autoantibodies and the clinical phenotype using multivariable logistic regression. Results: The LIA exhibited a sensitivity of 65.4% and a specificity of 65.4%, at the optimal cutoff values of 2 + signal intensity. By taking the result of ANA into consideration, the optimal cutoff point was redefined as 1+. We observed a higher risk of diffuse cutaneous SSc (dcSSc) in those with negative autoantibodies, positive anti-Scl-70, anti-RNA polymerase III, and anti-Ro-52. Interstitial lung disease (ILD) was associated with negative autoantibodies, as well as positive anti-Scl-70 and anti-Ro52. Anti-Ro52 positivity was also associated with pulmonary arterial hypertension (PAH) and gastrointestinal tract involvement. Conclusion: The presence of anti-Ro52 or the absence of SSc-specific autoantibodies may potentially indicate advanced diseases in patients with SSc. The incorporation of both IIF and LIA testing may improve the diagnostic specificity of SSc.

KW - Anti-Ro52

KW - Autoantibody

KW - Immunoblot

KW - Interstitial lung disease

KW - Pulmonary arterial hypertension

KW - Systemic sclerosis

UR - http://www.scopus.com/inward/record.url?scp=85164264467&partnerID=8YFLogxK

U2 - 10.1016/j.cca.2023.117457

DO - 10.1016/j.cca.2023.117457

M3 - Article

C2 - 37390945

AN - SCOPUS:85164264467

SN - 0009-8981

VL - 547

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

M1 - 117457

ER -

The diagnostic and prognostic value of a line immunoblot assay in Taiwanese patients with systemic sclerosis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this